News
ACHV
--
0.00%
--
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th \- 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global ...
ACCESSWIRE · 5d ago
Achieve Life Sciences Announces Participation at Best Ideas Virtual Investor Conference
SEATTLE and VANCOUVER, British Columbia, May 13, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation a...
GlobeNewswire · 05/13 12:00
Achieve Life Sciences: Q1 Earnings Insights
Achieve Life Sciences (NASDAQ:ACHV) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 05/12 22:40
Achieve Life Sciences GAAP EPS of -$0.80 in-line
Achieve Life Sciences press release (NASDAQ:ACHV): Q1 GAAP EPS of -$0.80 in-line. As of March 31, 2022, the company’s cash, cash equivalents, and restricted cash was $36.4 million. 
Seekingalpha · 05/12 20:04
BRIEF-Achieve Reports Results For Q1 2022
reuters.com · 05/12 20:01
Achieve Life Sciences Q1 EPS $(0.80) Beats $(0.81) Estimate
Achieve Life Sciences (NASDAQ:ACHV) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(0.81) by 1.23 percent. This is a 38.46 percent increase over losses of $(1.30) per share
Benzinga · 05/12 20:00
Health Check: How Prudently Does Achieve Life Sciences (NASDAQ:ACHV) Use Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Simply Wall St. · 05/05 18:59
ACHV: Topline Data from ORCA-2 Smoking Cessation Trial
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT
Benzinga · 05/03 09:31
Oppenheimer Adjusts Price Target on Achieve Life Sciences to $27 From $23, Keeps Outperform Rating
MT Newswires · 04/28 06:29
Achieve Life Sciences Aces Pivotal Cytisinicline Study In Smoking Cessation
Benzinga · 04/27 13:40
BRIEF-Achieve Life Sciences Reports Statistically Significant Smoking Cessation Results In Trial Of Cytisinicline In Adult Smokers
reuters.com · 04/27 12:13
Achieve Life Sciences Announces Successful, Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers
Clinically robust and statistically significant results in primary and secondary endpoints for both 6- and 12-week cytisinicline treatment compared to placebo Primary endpoints demonstrated 6-8x increased odds of smoking abstinence with cytisinicline compa...
GlobeNewswire · 04/27 12:00
Achieve Life Sciences Says Its Smoking Addiction Treatment Candidate Showed Better Quit Rates Than Placebo in Phase 3 Trial
MT Newswires · 04/27 11:20
Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 12, 2022
SEATTLE and VANCOUVER, British Columbia, April 21, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation...
GlobeNewswire · 04/21 12:00
ACHV: 2021 Results: ORCA-3 Underway, ORCA-V1 Soon to Start
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT
Benzinga · 03/16 12:01
Achieve Life Sciences Announces Cytisinicline Presentation at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
SEATTLE and VANCOUVER, British Columbia, March 15, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation...
GlobeNewswire · 03/15 12:00
BRIEF-Achieve Life Sciences Announces Expansion Of Manufacturing & Quality Operations Team And Granting Of Inducement Award
reuters.com · 03/11 13:08
Achieve Life Sciences Announces Expansion of Manufacturing & Quality Operations Team and Granting of Inducement Award
SEATTLE and VANCOUVER, British Columbia, March 11, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation...
GlobeNewswire · 03/11 13:00
Webull provides a variety of real-time ACHV stock news. You can receive the latest news about Achieve Life Sciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACHV
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid from the seeds of the Laburnum anagyroides plant. Cytisinicline is structurally similar to nicotine and a mechanism of action that is both agonistic and antagonistic. It is aid in smoking cessation, or nicotine addiction, by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms through agonistic effects on nicotine receptors and by reducing the reward and satisfaction associated with nicotine through antagonistic properties.